| Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind … HGM Heijerman, EF McKone, DG Downey, E Van Braeckel, SM Rowe, ... The Lancet 394 (10212), 1940-1948, 2019 | 1001 | 2019 |
| Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation FJ Accurso, SM Rowe, JP Clancy, MP Boyle, JM Dunitz, PR Durie, ... New England Journal of Medicine 363 (21), 1991-2003, 2010 | 916 | 2010 |
| Mucus clearance and lung function in cystic fibrosis with hypertonic saline SH Donaldson, WD Bennett, KL Zeman, MR Knowles, R Tarran, ... New England Journal of Medicine 354 (3), 241-250, 2006 | 857 | 2006 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 759 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 672 | 2021 |
| Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation JP Clancy, SM Rowe, FJ Accurso, ML Aitken, RS Amin, MA Ashlock, ... Thorax 67 (1), 12-18, 2012 | 651 | 2012 |
| Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... American journal of respiratory and critical care medicine 190 (2), 175-184, 2014 | 522 | 2014 |
| Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure AG Henderson, C Ehre, B Button, LH Abdullah, LH Cai, MW Leigh, ... The Journal of clinical investigation 124 (7), 3047-3060, 2014 | 346 | 2014 |
| Regulation of the epithelial sodium channel by serine proteases in human airways SH Donaldson, A Hirsh, DC Li, G Holloway, J Chao, RC Boucher, ... Journal of Biological Chemistry 277 (10), 8338-8345, 2002 | 320 | 2002 |
| Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia R Tarran, L Trout, SH Donaldson, RC Boucher The Journal of general physiology 127 (5), 591-604, 2006 | 254 | 2006 |
| CFTR modulator theratyping: Current status, gaps and future directions JP Clancy, CU Cotton, SH Donaldson, GM Solomon, DR VanDevanter, ... Journal of Cystic Fibrosis 18 (1), 22-34, 2019 | 244 | 2019 |
| Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? HAWM Tiddens, SH Donaldson, M Rosenfeld, PD Paré Pediatric pulmonology 45 (2), 107-117, 2010 | 220 | 2010 |
| Sodium channels and cystic fibrosis SH Donaldson, RC Boucher Chest 132 (5), 1631-1636, 2007 | 206 | 2007 |
| Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR SH Donaldson, JM Pilewski, M Griese, J Cooke, L Viswanathan, E Tullis, ... American journal of respiratory and critical care medicine 197 (2), 214-224, 2018 | 203 | 2018 |
| A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease DB Hill, PA Vasquez, J Mellnik, SA McKinley, A Vose, F Mu, ... PloS one 9 (2), e87681, 2014 | 198 | 2014 |
| SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage A Garcia-Caballero, JE Rasmussen, E Gaillard, MJ Watson, JC Olsen, ... Proceedings of the national academy of sciences 106 (27), 11412-11417, 2009 | 198 | 2009 |
| Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial DP Nichols, AC Paynter, SL Heltshe, SH Donaldson, CA Frederick, ... American journal of respiratory and critical care medicine 205 (5), 529-539, 2022 | 195 | 2022 |
| Update on pathogenesis of cystic fibrosis lung disease SH Donaldson, RC Boucher Current opinion in pulmonary medicine 9 (6), 486-491, 2003 | 186 | 2003 |
| Basal nucleotide levels, release, and metabolism in normal and cystic fibrosis airways SH Donaldson, ER Lazarowski, M Picher, MR Knowles, MJ Stutts, ... Molecular Medicine 6, 969-982, 2000 | 122 | 2000 |
| Extracellular purines are biomarkers of neutrophilic airway inflammation CR Esther, NE Alexis, ML Clas, ER Lazarowski, SH Donaldson, ... European Respiratory Journal 31 (5), 949-956, 2008 | 106 | 2008 |
